Index to Advertisers

Columbus Instruments
   Datamax/IBM Computer .......... A8
Current Science
   Journal of Hypertension .......... A14
Gould Recording Systems
   ES2000 .................................. A7
The Graduate Hospital
   Continuing Education .......... A6
International Society of Hypertension
   Continuing Education .......... A13
Japanese Heart Journal .......... A26
Marion Laboratories
   Cardizem SR ................. A9–A12
Merck Sharp & Dohme
   Vasotec ......................... A27–A30
Pfizer Laboratories
   Minipress ................. Covers 3 & 4
   Procardia ................ A15–A16
Rorer Pharmaceuticals
   Lozol .......................... Cover 2–A2
Syntex Laboratories
   Cardene ......................... A17–A22

Vicki Sullivan
Scientific Publishing
Director

American Heart Association, 7320 Greenville Avenue, Dallas, Texas 75231

Advertising Sales
Pharmaceutical Media Inc.
440 Park Avenue, South
New York, NY 10016
(212) 685-5010

All possible care is taken in preparing this index.
AHA is not responsible for errors or omissions.
MINIPRESS (prazosin HCl)

Blood pressure control that leaves other CHD risk factors unaffected

1. Effectively reduces high blood pressure—by reducing peripheral vascular resistance

2. Does not adversely affect the lipid profile:
   - Thiazide diuretics and beta blockers have been shown to produce adverse lipid changes which may negate the benefit of blood pressure reduction

3. Does not impair exercise capacity.
   - Resting heart rate and cardiac output are not reduced—so patients can continue to engage in dynamic exercise and pursue an active lifestyle

4. Has no significant effect on glucose metabolism—so control in diabetic patients is not compromised.
   - Thiazide diuretics and beta blockers may have untoward effects in diabetic hypertensives or block the symptoms of hypoglycemia

References:
In hypertension, there's safety in these numbers.

MINIPRESS® (prazosin HCl)
Blood pressure control that leaves other CHD risk factors unaffected

1. Effectively reduces high blood pressure
2. Does not adversely affect the lipid profile
3. Does not impair exercise capacity
4. Has no significant effect on glucose metabolism

MINIPRESS® Capsules 1 mg, 2 mg, 5 mg
For Initial Therapy of Hypertension

Most common side effects, generally mild and transient, are: dizziness, headache, drowsiness, palpitations, and nausea. Syncope has been reported in about 0.15% of patients at the recommended initial dose of 1 mg.

Please see MINIPRESS® (prazosin HCl) brief summary on adjacent page.